Kwality Pharmaceuticals Limited (BOM:539997)
India · Delayed Price · Currency is INR 1,512.85
+59.40 (4.09%)
At close: Mar 5, 2026
Kwality Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 4,616 | 3,702 | 3,072 | 2,510 | 4,562 | 2,620 |
Other Revenue | - | - | - | - | - | 10.42 |
| 4,616 | 3,702 | 3,072 | 2,510 | 4,562 | 2,631 | |
Revenue Growth (YoY) | 33.23% | 20.52% | 22.36% | -44.97% | 73.42% | 84.59% |
Cost of Revenue | 2,383 | 1,882 | 1,580 | 1,136 | 2,051 | 1,716 |
Gross Profit | 2,234 | 1,820 | 1,492 | 1,375 | 2,511 | 914.74 |
Selling, General & Admin | 541.9 | 454.65 | 326.29 | 301.26 | 202.76 | 160.1 |
Other Operating Expenses | 615.17 | 544.8 | 485.2 | 456.86 | 573.94 | 452.81 |
Operating Expenses | 1,353 | 1,182 | 1,007 | 907.71 | 883.61 | 677.85 |
Operating Income | 880.37 | 637.51 | 484.53 | 466.8 | 1,627 | 236.9 |
Interest Expense | -105.76 | -98.78 | -103.87 | -60.2 | -29.17 | -26.75 |
Interest & Investment Income | 1.62 | 1.62 | 1.3 | 1.23 | 1.23 | 1.81 |
Currency Exchange Gain (Loss) | 0.77 | 0.77 | - | 12.66 | 16.62 | 0.96 |
Other Non Operating Income (Expenses) | -0 | -0 | - | -0 | -0 | - |
EBT Excluding Unusual Items | 776.99 | 541.12 | 381.96 | 420.48 | 1,616 | 212.91 |
Gain (Loss) on Sale of Assets | 0.28 | 0.28 | 0.02 | 0.54 | - | -0.2 |
Asset Writedown | - | - | - | -70.51 | - | - |
Other Unusual Items | -8.29 | - | -70.99 | -94.78 | - | - |
Pretax Income | 768.98 | 541.4 | 310.99 | 255.72 | 1,616 | 212.72 |
Income Tax Expense | 203.83 | 143.37 | 74.83 | 62.93 | 416.28 | 63.84 |
Earnings From Continuing Operations | 565.15 | 398.03 | 236.16 | 192.8 | 1,199 | 148.88 |
Minority Interest in Earnings | 0.19 | 0.42 | 1.8 | 0.93 | 0.53 | 2.58 |
Net Income | 565.34 | 398.45 | 237.96 | 193.72 | 1,200 | 151.46 |
Net Income to Common | 565.34 | 398.45 | 237.96 | 193.72 | 1,200 | 151.46 |
Net Income Growth | 89.69% | 67.44% | 22.84% | -83.86% | 692.24% | 82.11% |
Shares Outstanding (Basic) | 10 | 10 | 10 | 10 | 10 | 10 |
Shares Outstanding (Diluted) | 10 | 10 | 10 | 10 | 10 | 10 |
Shares Change (YoY) | 0.77% | - | - | - | 0.00% | - |
EPS (Basic) | 54.42 | 38.40 | 22.93 | 18.67 | 115.64 | 14.60 |
EPS (Diluted) | 54.42 | 38.40 | 22.93 | 18.67 | 115.64 | 14.60 |
EPS Growth | 88.25% | 67.44% | 22.84% | -83.86% | 692.22% | 82.11% |
Free Cash Flow | - | 294.25 | 131.42 | -62.92 | 54.45 | 33.06 |
Free Cash Flow Per Share | - | 28.36 | 12.66 | -6.06 | 5.25 | 3.19 |
Gross Margin | 48.39% | 49.16% | 48.56% | 54.75% | 55.04% | 34.77% |
Operating Margin | 19.07% | 17.22% | 15.77% | 18.59% | 35.66% | 9.01% |
Profit Margin | 12.25% | 10.76% | 7.75% | 7.72% | 26.30% | 5.76% |
Free Cash Flow Margin | - | 7.95% | 4.28% | -2.51% | 1.19% | 1.26% |
EBITDA | 1,054 | 820.4 | 680.12 | 616.38 | 1,734 | 301.83 |
EBITDA Margin | 22.83% | 22.16% | 22.14% | 24.55% | 38.01% | 11.47% |
D&A For EBITDA | 173.38 | 182.9 | 195.59 | 149.58 | 106.91 | 64.93 |
EBIT | 880.37 | 637.51 | 484.53 | 466.8 | 1,627 | 236.9 |
EBIT Margin | 19.07% | 17.22% | 15.77% | 18.59% | 35.66% | 9.01% |
Effective Tax Rate | 26.51% | 26.48% | 24.06% | 24.61% | 25.77% | 30.01% |
Revenue as Reported | 4,642 | 3,721 | 3,090 | 2,540 | 4,597 | 2,636 |
Advertising Expenses | - | 16.81 | 0.66 | 1.67 | 1.25 | 0.73 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.